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Abstract 47 
 48 
Importance: More patients with cancer use hospice today than ever before, but there are 49 
indications that care intensity outside of hospice is increasing, and length of hospice stay 50 
decreasing. Uncertainties regarding how hospice affects health care utilization and costs have 51 
hampered efforts to promote it. 52 
 53 
Objective: To compare utilization and costs of patients with poor-prognosis cancers enrolled in 54 
hospice to similar patients without hospice care.  55 
 56 
Design: Matched case–control study of hospice and non-hospice care.  57 
 58 
Setting: Nationally-representative 20% sample of Medicare fee-for-service beneficiaries who 59 
died in 2011.  60 
 61 
Participants: Patients with poor-prognosis cancers (e.g., brain, pancreatic, metastatic 62 
malignancies) enrolled in hospice before death, matched to similar patients who died without 63 
hospice care. Matched pairs in which either patient received cancer-directed treatment after 64 
exposure were excluded. 65 
 66 
Exposure: Defined as the time period between hospice enrollment and death for hospice 67 
beneficiaries, and the equivalent period of non-hospice care before death for matched controls. 68 
 69 
Main Outcomes: Health care utilization including hospitalizations and procedures; place of 70 
death; cost trajectories before and after hospice start; and cumulative costs, all over the last year 71 
of life.  72 
 73 
Results: Among 86,851 patients with poor-prognosis cancers, median time from first poor-74 
prognosis diagnosis to death was 13 months (IQR: 3-34), and 51,924 (60%) entered hospice 75 
before death. Matching yielded a cohort balanced on age, sex, region, time from poor-prognosis 76 
diagnosis to death, and baseline care utilization, with 18,165 patients in the hospice group and 77 
18,165 in the non-hospice group. After matching, 11% of non-hospice and 1% of hospice 78 
beneficiaries who had cancer-directed therapy after exposure were excluded. Median hospice 79 
duration was 11 days. Non-hospice beneficiaries had significantly more hospitalizations (65%, 80 
95% CI: 64-66%, vs. hospice: 42%, 95% CI 42-43%, risk ratio: 1.5, 95% CI: 1.5-1.6), intensive 81 
care (36%, 95% CI: 35-37%, vs. hospice: 15%, 95% CI: 14-15%, risk ratio: 2.4, 95% CI: 2.3-2.5), 82 
and procedures (51%, 95% CI: 50-52%, vs. hospice: 27%, 95% CI: 26-27%, risk ratio: 1.9, 95% 83 
CI: 1.9-2.0), largely for acute conditions not directly related to cancer; 74% (95% CI: 74-75) of 84 
non-hospice beneficiaries died in hospitals and nursing facilities compared to 14% (95% CI: 14-85 
15%) of hospice. Costs for hospice and non-hospice beneficiaries were not significantly different 86 
at baseline, but diverged after hospice start. Total costs over the last year of life were $71,517 87 
(95% CI: $70,543-72,490) for non-hospice and $62,819 (95% CI: $62,082-63,557) for hospice, a 88 
statistically-significant difference of $8,697 (95% CI: $7,560-9,835).  89 
Conclusions and Relevance: In this sample of Medicare fee-for-service beneficiaries with poor-90 
prognosis cancer, those receiving hospice care, compared to matched control patients not 91 
receiving hospice care, had significantly lower rates of hospitalization, intensive care unit 92 
admission, and invasive procedures at the end of life, along with significantly lower total costs 93 
during the last year of life. 94 
  95 
Introduction 96 
 97 
Multiple studies have documented the high intensity of medical care at the end of life,1,2 and there 98 
is increasing consensus that such care can produce poor outcomes2–4 and conflict with patient 99 
preferences.4,5 The Institute of Medicine report Dying in America has drawn attention to the 100 
difficulties of promoting palliative care, including Medicare’s hospice program,6 the nation’s 101 
largest palliative care intervention, which covers all comfort-oriented care related to terminal 102 
illnesses, from medications to home care to hospitalizations. While the number of people 103 
receiving hospice has increased since the program began in 1982, enrollment length decreased 104 
over the same period, and end of life care intensity increased.7 Patients with cancer, the single 105 
largest group of hospice users,8 have both the highest rates of hospice enrollment and the highest 106 
rates of hospice stays under three days.7  107 
 108 
Several policy factors are cited to explain these trends. First, the Medicare administration 109 
monitors and prosecutes hospices with inappropriately long hospice stays, creating a perceived 110 
disincentive for providers to make early hospice referrals that are more likely to produce long 111 
stays.9,10 Second, Medicare does not reimburse providers for discussions to elicit patients’ 112 
preferences for end of life care.11 Third, Medicare requires patients to formally renounce curative 113 
care before enrolling in hospice, which is thought to limit demand.10,12 This last issue is 114 
particularly relevant to cancer care, since patients often wish to continue active treatment 115 
irrespective of prognosis—an area of concern to payers as use of costly new targeted therapies, 116 
often oral and less toxic, becomes widespread at the end of life.13  117 
 118 
Indeed, many of these policies are related to concerns that increasing hospice use could increase 119 
health care utilization and ultimately costs—while advocates of hospice argue that aggressive 120 
end-of-life care outside of hospice is the more pressing cost issue.10,14 A key input to these 121 
debates is a better understanding of the relationship between hospice and health care utilization, 122 
and its implications for costs. To date, however, few studies have described the realities of how 123 
hospice affects medical care at the end of life, and attempts to estimate cost savings have 124 
produced mixed results, with two recent studies finding only small differences in costs that were 125 
inconsistent across different lengths of hospice stays.10,15 Using data on Medicare beneficiaries 126 
with poor-prognosis cancers, we matched those enrolled in hospice before death to those who 127 
died without hospice care, and compared utilization and costs at the end of life. We excluded 128 
patients who received cancer-directed treatment during hospice, or the equivalent period before 129 
death for non-hospice beneficiaries, to compare beneficiaries who may have had similar 130 
preferences for no further cancer treatment. 131 
 132 
 133 
Methods 134 
 135 
Study population 136 
 137 
In a nationally-representative 20% sample of fee-for-service Medicare beneficiaries (74% of the 138 
Medicare population, excluding managed care), we identified those with poor-prognosis 139 
malignancies who died in 2011 after a full year of Medicare coverage. By virtue of having died 140 
after poor-prognosis diagnoses, these beneficiaries would have been eligible for hospice, 141 
available to those with terminal illness and expected survival of under six months. We assumed 142 
beneficiaries had enough evidence of advanced disease to make hospice enrollment reasonable.  143 
 144 
Data  145 
 146 
We created a list of International Classification of Disease (ICD) codes corresponding to poor-147 
prognosis malignancies, derived from a palliative care screening instrument at a major US cancer 148 
center, including poor-prognosis primaries (e.g., lung, pancreatic, brain), any metastatic or ill-149 
defined malignancy, and hematologic malignancies designated as relapsed or not in remission 150 
(eTable 1).16 We retained beneficiaries with any of these codes present in claims between 2007-151 
11 in the inpatient, outpatient, and carrier hospice files, excluding potential outpatient ‘rule-out’ 152 
codes.17 We attributed to hospice all care received by the beneficiary from enrollment (i.e., day of 153 
first hospice claim) until death, and assumed beneficiaries remained in hospice until death; 98.6% 154 
had a hospice claim within 30 days of death. We excluded those with hospice claims prior to 155 
poor-prognosis cancer diagnoses, indicating enrollment for another, prior disease.  156 
 157 
Matching 158 
 159 
We used a two stage matching approach to create pairs of beneficiaries who were as similar as 160 
possible, but made different choices regarding hospice enrollment at the same point in time 161 
before death. First, we matched hospice beneficiaries to a control group of beneficiaries who did 162 
not choose hospice. Second, for each matched pair, we matched the hospice period to the 163 
equivalent ‘exposure period’ of non-hospice care before death. By matching hospice beneficiaries 164 
to non-hospice beneficiaries, then comparing outcomes before and after hospice enrollment, we 165 
attempted to capture what might have happened if the non-hospice beneficiary had instead 166 
enrolled in hospice.  167 
 168 
To match beneficiaries, we split the sample into those who enrolled in hospice at any time before 169 
death, and those who did not. Our initial plan was to perform propensity score matching (PSM), 170 
but this resulted in multiple significant imbalances between groups, which persisted despite 171 
attempts to rematch on different covariates. As a result, we used coarsened exact matching18 172 
(CEM); we present these results here, and detailed PSM results in the supplement (eMethods). 173 
We matched using four variables: place of residence, age, sex, and time from first poor-prognosis 174 
cancer diagnosis to death. We assumed illness duration from diagnosis to death was inversely 175 
correlated with disease severity and thus a good proxy measure for it; we also assumed that 176 
hospice enrollment did not affect illness duration. We first matched on the finest strata of all 177 
variables (home zip code, year of birth, sex, illness duration in months), then iteratively coarsened 178 
variables and re-matched beneficiaries unmatched in the first round, to a maximum coarseness of 179 
five-year age intervals, four-month illness duration intervals, and home hospital referral region 180 
(HRR; see eTable2).  181 
 182 
To match exposure periods, i.e., ‘treatment’ period of hospice care to ‘control’ period of the same 183 
length before death, we defined the hospice period as the number of days, dh, of hospice care 184 
prior to death, ݐௗ௘௔௧௛௛ , and defined the corresponding exposure period for matched non-hospice 185 
beneficiaries as dh days prior to death. Thus a beneficiary who began hospice on day ݐ଴௛ and died 186 
dh days later on ݐௗ௘௔௧௛௛  was matched to a non-hospice beneficiaries who died on ݐௗ௘௔௧௛௡ , whose 187 
exposure period began dh days earlier (Figure 1B).  188 
 189 
We identified beneficiaries receiving chemotherapy or curative surgery before and after exposure 190 
using claims-based codes (eTable 3).20,21 We excluded pairs where one or both beneficiaries 191 
received cancer-directed treatment after exposure, creating a cohort matched on preference for no 192 
further treatment, in order to better identify differences in utilization and cost associated with 193 
hospice, rather than simply with the decision to abandon cancer treatment.  194 
 195 
Statistical analysis 196 
 197 
We verified balance between hospice and non-hospice beneficiaries by comparing means or 198 
medians for all variables used for matching. We also compared care utilization before hospice 199 
enrollment including clinic, emergency, inpatient, home health, and skilled nursing facility (SNF) 200 
use; and comorbidity, measured on a scale synthesizing Elixhauser and Charlson indices.19 We 201 
calculated comorbidity over two periods: from the earliest data available (2006) to first poor-202 
prognosis cancer diagnosis (median 4.4 years), and from diagnosis to exposure (median 5.5 203 
months). We could not match on pre-exposure utilization or comorbidity: non-hospice 204 
beneficiaries have no intrinsic ‘exposure periods’—these could only be defined after matching, 205 
with respect to hospice enrollment for matched hospice beneficiaries.  206 
 207 
The primary outcome was health care utilization during exposure periods, i.e., hospice care, or 208 
the equivalent period for the matched controls, in the last year of life. We measured frequency of 209 
hospitalizations, intensive care, inpatient procedures, and death in hospitals or SNFs, ascertained 210 
by the presence of a facility claim on the death date. The secondary outcome was total costs, 211 
calculated at the beneficiary-week level, starting one year before death or six months before 212 
exposure (whichever was earlier). We added amount paid by beneficiaries, Medicare, and third-213 
party payers22 for all inpatient and outpatient care,23 including hospice and provider payments, but 214 
excluding outpatient medication claims, personal care, and other expenses not covered by 215 
Medicare. The Institutional Review Board of the National Bureau of Economic Research 216 
approved this study. Statistical analyses were performed using Stata 13 (Stata Corporation, 217 
College Station, Tex) and R 3.0.2 (R Foundation, Vienna, Austria). 218 
 219 
 220 
Results 221 
 222 
Study population 223 
 224 
In this nationally-representative 20% sample of Medicare fee-for-service beneficiaries with poor-225 
prognosis cancer, median time from first poor-prognosis diagnosis to death was 13 months (IQR: 226 
3-34); 60% received hospice care. Figure 1A shows creation of the matched cohort from this 227 
population. Figure 1B shows creation of exposure periods, matching hospice periods to 228 
equivalent periods of non-hospice care for matched controls. Of 86,851 deaths with poor-229 
prognosis cancer, we matched 41,224 beneficiaries, or 59% of the smaller non-hospice group. 230 
After hospice enrollment, 1% of hospice beneficiaries received cancer-directed therapy, 231 
compared to 11% of non-hospice beneficiaries over similar exposure periods before death. Pairs 232 
including these beneficiaries were excluded. The final cohort of 36,330 beneficiaries was largely 233 
similar to the overall population of 86,851 cancer deaths from which it was drawn (eTable 4), but 234 
had shorter median time from diagnosis to death (reflecting fewer exact matches on illness 235 
duration among beneficiaries with longer survival times—eFigure 1), and lived in zip codes with 236 
mean incomes 1-3% higher than the overall cohort.  237 
 238 
Table 1 shows baseline characteristics of the matched cohort. There were no statistically-239 
significant differences between cases and controls in age, sex, region, time from poor-prognosis 240 
diagnosis to death, comorbidity before poor-prognosis diagnosis, or daily cost in the year before 241 
hospice enrollment. Solid tumors accounted for the majority of diagnoses in both groups (91% 242 
hospice, 88% non-hospice). Hospice beneficiaries were more white, and lived in higher-income 243 
zip codes. Median hospice duration was 11 days; under 6% of stays exceeded six months. 244 
Hospice and non-hospice beneficiaries had similar comorbidity before poor-prognosis diagnosis, 245 
but higher comorbidity between diagnosis and hospice enrollment; illness duration from 246 
diagnosis to death, however, was the same for both groups (7 months). Before exposure, hospice 247 
beneficiaries had similar prevalence of dementia, anemia, fluid/electrolyte disturbances, 248 
hemiplegia, and weight loss compared to non-hospice beneficiaries; hospice beneficiaries had 249 
more days of home health assistance (7 vs. 6, difference: 1, 95% CI: 0.4-1.6), but used SNFs less 250 
(46.5% vs. 52.6%, difference: 6.2%, 95% CI: 5.1-7.2%). Together, these results indicated 251 
similarity between hospice and non-hospice beneficiaries on important aspects of functional 252 
status. Finally, hospice beneficiaries had more clinic visits (45 vs. 42, difference: 3, 95% CI: 2-4) 253 
and more claims for cancer-directed therapy (44.5% vs. 35.5%, difference: 9%, 95% CI: 8-10%) 254 
before hospice start.  255 
 256 
Utilization and costs 257 
 258 
Table 2 compares health care utilization during hospice with the equivalent period before death 259 
for matched non-hospice beneficiaries, in the last year of life. Non-hospice beneficiaries had 260 
more hospitalizations, largely for acute conditions (e.g., infections, organ failure) and 261 
exacerbations of medical comorbidities. Only one of the ten most frequent primary discharge 262 
diagnoses involved cancer. Rates of intensive care and invasive procedures were also higher for 263 
non-hospice beneficiaries. Seventy-four percent of non-hospice beneficiaries died in hospitals or 264 
SNFs, compared to 14% of hospice.  265 
 266 
We compared total costs for hospice and non-hospice beneficiaries before and after hospice start, 267 
to capture overall intensity of care utilization, and yield insight into whether differences in 268 
utilization were associated with hospice, or with pre-existing patient characteristics or care 269 
preferences. Figure 2 shows daily costs for representative groups of beneficiaries, separated by 270 
length of hospice enrollment. Over the year before hospice, hospice beneficiaries cost on average 271 
$145 daily (95% CI: $143-147) compared to $148 (95% CI: $146-150) for non-hospice 272 
(difference: $3, 95% CI: $0-5). In the week before hospice, hospice beneficiaries cost $802 daily, 273 
$146 (95% CI: $126-166) more than non-hospice beneficiaries. Costs declined rapidly thereafter, 274 
and by the last week of life, hospice beneficiaries cost $556 daily (95% CI: $542-571) compared 275 
to $1,760 (95% CI: $1,718-1,801) for non-hospice, a difference of $1,203 (95% CI: $1,161-276 
1,245).  277 
 278 
Table 3 shows cumulative total costs over the last year of life, by length of hospice enrollment; 279 
we calculated total costs over the last year, irrespective of exposure period start, for comparability 280 
to other studies. Overall, costs over the last year of life were $62,819 (95% CI: $62,082-63,557) 281 
for hospice and $71,517 (95% CI: $70,543-72,490) for non-hospice, a difference of $8,697 (95% 282 
CI: $7,560-9,835). Beneficiaries enrolled in hospice for 5-8 weeks had cumulative costs of 283 
$56,986 (95% CI: $55,098-58,875) compared to $74,890 (95% CI: $71,910-77,869) for non-284 
hospice beneficiaries, a difference of $17,903 (95% CI: $14,543-21,264). Differences in cost for 285 
short hospice stays (1-2 weeks) were smaller, but remained statistically significant. For the 2% of 286 
beneficiaries with hospice stays over one year, hospice beneficiaries had higher costs (difference: 287 
$7,387, 95% CI: $1,485-13,289).  288 
 289 
Propensity score analysis 290 
 291 
Propensity scores allowed us to match 100% of the smaller non-hospice group (eFigure 2), but 292 
produced imbalance on important covariates including baseline cost and geography, with median 293 
distance between pairs over 800 miles; only 0.8% of matched pairs lived in the same HRR 294 
(eTable 5). There was significant imbalance on time from poor-prognosis diagnosis to death, 436 295 
days for non-hospice and 286 for hospice, which likely contributed to significant differences in 296 
costs over the year before exposure ($149 for non-hospice vs. $135 for hospice; eTable 6): this 297 
year would have included a median of 79 days before hospice beneficiaries received their poor-298 
prognosis diagnosis, spuriously lowering cost estimates. Despite this, cost trajectories (eFigure 3) 299 
were grossly similar to the CEM cohort, and care utilization patterns were nearly identical 300 
(eTable 7). Cumulative costs over the last year of life (eTable 8) were $71,860 (95% CI: $71,094-301 
72,626) for non-hospice and $59,037 (95% CI: $58,353-59,538) for hospice (difference : $12,823, 302 
95% CI: $11,921-13,726).  303 
 304 
Discussion 305 
 306 
In a matched cohort of Medicare beneficiaries with poor-prognosis cancers, we found large, 307 
statistically-significant differences in care utilization between hospice and non-hospice 308 
beneficiaries at the end of life. While enrolled in hospice, beneficiaries were hospitalized less, 309 
received less intensive care, underwent fewer procedures, and were less likely to die in hospitals 310 
and SNFs. Over similar periods before death, one in ten non-hospice beneficiaries received active 311 
cancer-directed treatment; among those who did not, most were admitted to hospitals and ICUs 312 
for acute conditions not directly related to their poor-prognosis cancer. Such care is unlikely to fit 313 
with the preferences of most patients. Our findings highlight the potential importance of honest 314 
discussions between doctors and patients about the realities of care at the end of life, an issue of 315 
particular importance as the Medicare administration weighs decisions around reimbursing 316 
providers for advance care planning.  317 
 318 
Differences in care utilization between hospice and non-hospice beneficiaries translated into 319 
statistically-significantly lower costs for hospice beneficiaries in the last year of life. Cost 320 
trajectories began to diverge in the week after hospice enrollment, implying that baseline 321 
differences between hospice and non-hospice beneficiaries were not responsible for cost 322 
differences. Hospice enrollment of 5-8 weeks produced the greatest savings; shorter stays 323 
produced fewer savings, likely because of both hospice initiation costs, and need for intensive 324 
symptom palliation in the days before death.24 Overall, these results may indicate that efforts to 325 
promote broader and earlier hospice uptake are unlikely to produce increases in total costs.  326 
 327 
Our study in no way replicates a randomized trial of a hospice intervention, and results depend on 328 
the validity of the matching strategy, making it important to highlight key choices involved in the 329 
creation of the study cohort. First, CEM achieved excellent balance for matched beneficiaries, but 330 
failed to match a substantial number of beneficiaries (41% of the smaller non-hospice group, 53% 331 
of the overall cohort). PSM matched 100% of the non-hospice group and 80% of the overall 332 
cohort, but at the expense of inferior balance on important covariates. Each method had trade-offs 333 
in terms of internal and external validity, but both ultimately produced very similar results. 334 
Second, matching on illness duration made two crucial assumptions: that illness duration was a 335 
proxy for disease severity, and that it was not affected by hospice enrollment. Matching on 336 
duration would bias results if hospice prolonged life: hospice patients with more severe disease at 337 
baseline, who improved after hospice treatment, would be matched to controls with less severe 338 
baseline disease. Since utilization and severity are usually correlated, our estimates of differences 339 
would be biased downward. If hospice beneficiaries had shorter survival, e.g., because of 340 
discontinuation of effective anti-cancer treatment, the opposite would be true; but since cancer-341 
directed therapy was more common for hospice beneficiaries before enrollment, insufficiently 342 
aggressive treatment seems unlikely. Third, hospice beneficiaries had higher comorbidity scores 343 
after poor-prognosis diagnoses, which could reflect higher overall utilization, or higher true 344 
comorbidity. The latter would have biased downward our estimates of savings, though matching 345 
on illness duration should have controlled for overall disease severity in this period. Fourth, our 346 
results are unlikely to generalize to this sub-group of 1% of hospice beneficiaries who received 347 
cancer-directed treatment after exposure start. Further, we could not determine if other hospice 348 
beneficiaries left hospice. If this were widespread, contamination would lead to downward bias in 349 
estimates of differences in outcomes. Finally, hospice beneficiaries lived in wealthier areas, 350 
potentially giving them increased access to hospice. However, since pairs were matched by HRR, 351 
geographic access to hospice should have been similar, except possibly in large-area rural HRRs.  352 
 353 
There are other limitations to note. We restricted our analysis to beneficiaries with poor-prognosis 354 
cancer, but non-cancer diagnoses are a growing part of the hospice population, and our results 355 
may not generalize. We excluded beneficiaries with managed care, for whom claims data were 356 
not available, and the entire non-Medicare population. We relied on ICD codes to identify poor-357 
prognosis diagnoses, but claims-based diagnoses can be inaccurate. We determined place of death 358 
via same-day facility claims, which did not include inpatient hospice facilities or assisted living; 359 
we had incomplete data on SNF, and no data on personal care utilization. We did not include 360 
outpatient medication expenses; these were likely lower in the hospice group, since hospice 361 
covers medications related to their terminal condition.  362 
 363 
Conclusions 364 
 365 
In this sample of Medicare fee-for-service beneficiaries with poor-prognosis cancer, those 366 
receiving hospice care, compared to matched control patients not receiving hospice care, had 367 
significantly lower rates of hospitalization, intensive care unit admission, and invasive procedures 368 
at the end of life, along with significantly lower health care expenditures during the last year of 369 
life. 370 
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Figure legends 389 
 390 
Figure 1. Study population 391 
Panel A shows matching of hospice to non-hospice beneficiaries, starting with all fee-for-392 
service beneficiaries who died in 2011, and restricting to those with a poor-prognosis 393 
cancer diagnosis. Some beneficiaries were excluded because of missing data, and 394 
others because they started hospice prior to cancer diagnosis, likely due to another 395 
concurrent terminal illness. Panel B shows matching of exposure periods for two 396 
hypothetical beneficiaries matched in the first stage. In chronological time, the two 397 
beneficiaries are represented as lines spanning from poor-prognosis diagnosis to death; 398 
in the exposure time frame used for analysis, dates of death are aligned to create a 399 
similar exposure period of hospice or non-hospice care prior to death. Because 400 
beneficiaries are matched on time from diagnosis to death, the lengths of the lines are 401 
approximately the same. After matching exposure periods, we drop pairs in which one or 402 
both beneficiaries received chemotherapy or curative surgery during the periods. 403 
 404 
Figure 2. Cost trajectories before and after hospice start 405 
Figure 2 shows mean total daily costs relative to hospice start, with beneficiaries 406 
separated into groups based on the length of the exposure period (i.e., the length of 407 
hospice or non-hospice care before death). Since showing all 109 groups was not 408 
possible, and since aggregation would obscure time trends, we show representative 409 
groups with exposure periods of 1, 2, 3, and 4 weeks, which together make up 71% of 410 
the entire cohort; every 2 weeks from 6 to 12 weeks (8% of the cohort); and every 4 411 
weeks from 16 to 28 (2%). "X" marks week of death for each group of beneficiaries. The 412 
panel title shows the length of the exposure period in weeks, the number of beneficiaries, 413 
and the percentage of the overall matched cohort they make up. The shaded area 414 
around the lines show the 95% confidence interval (CI) for the mean; lower CI bounds of 415 
less than zero were censored at zero. Week zero is defined as the week before the first 416 
day of hospice. 417 
418 
Tables 419 
Table 1. Baseline characteristics of the matched cohort 
Variable Non-hospice  Hospice  Difference      Std. Diff. d 
  (N=18,165) (N=18,165)     
Variables used for matching 
  
Age in years, mean (95% CI) a  80 (79.9, 80.1) 80 (79.9, 80.1) 0 (-0.2, 0.2) 0.00 
Male, %  (95% CI)a 48 (47.3, 48.8) 48 (47.3, 48.8) 0 (-1, 1) 0.00 
Days from poor-prognosis 
cancer diagnosis to death, 
median (25th, 75th percentile) b 
213 (43, 818) 210 (48, 822) 3 (-10, 16) 0.00 
Distance between pair home zip 
codes in miles, median (25th, 
75th percentile) b 
24.5 (10.2, 51.8)  - 
Demographics 
White, %  (95% CI) a  84.7 (84.1, 85.2) 87.8 (87.3, 88.2) -3.1 (-3.8, -2.4) -0.09 
Income of beneficiary home zip 
code in thousands, median 
(25th, 75th percentile) b  
62.9 (51.5, 83.1) 64.9 (52.7, 86.6)  -2 (-2.6, -1.4) -0.08 
Region, % (95% CI) a 
Northeast 22.7 (22.1, 23.4) 22.8 (22.2, 23.4) 0 (-0.9, 0.8) 0.00 
Midwest  23.6 (23, 24.3) 23.8 (23.2, 24.4) -0.1 (-1, 0.7) 0.00 
South  37.8 (37.1, 38.5) 37.6 (36.9, 38.3) 0.2 (-0.8, 1.2) 0.00 
West 15.9 (15.3, 16.4) 15.9 (15.4, 16.4) 0 (-0.8, 0.7) 0.00 
First poor-prognosis malignancy diagnosis, % (95% CI) a 
Solid tumor  88.2 (87.7, 88.7) 91 (90.6, 91.5) -2.9 (-3.5, -2.2) -0.09 
Hematological 12.2 (11.7, 12.7) 9.4 (9, 9.8) 2.8 (2.2, 3.4) 0.09 
Illness and hospice course, median (25th, 75th percentile) b 
Poor-prognosis cancer diagnosis 
to exposure start, days 166 (24, 757) 165 (25, 758)  1 (-13.3, 11.3) 0.00 
Exposure start to death, days 11 (4, 35) 11 (4, 35) 0 (-0.4, 0.4) 0.00 
2006 to poor prognosis cancer 
diagnosis, days 
1767 (1185, 1942) 
 
1770 (1181, 1941) 
 
-3 (-14.4, 8.4) 
 
0.00 
 
Comorbidity index, median (25th, 75th percentile) b c 
2006 to poor-prognosis cancer 
diagnosis 3 (1, 6) 3 (1, 6) 0 (-0.1, 0.1) - e 
Poor-prognosis diagnosis to 
exposure start 6 (2, 9) 7 (4, 9)  -1 (-1.1, -0.9) - e 
Table 1. Baseline characteristics of the matched cohort 
Variable Non-hospice  Hospice  Difference      Std. Diff. d 
  (N=18,165) (N=18,165)     
Presence of selected individual comorbidities related to functional status, 2006 to exposure 
start, % (95% CI) a 
Anemia  68.5 (67.8, 69.2) 68.3 (67.6, 69) 0.2 (-0.7, 1.2) 0.00 
Dementia  18 (17.5, 18.6) 18 (17.5, 18.6) 0 (-0.8, 0.8) 0.00 
Fluid and electrolyte disorders  71.7 (71, 72.3) 71.2 (70.5, 71.9) 0.5 (-0.5, 1.4) 0.01 
Hemiplegia  6.7 (6.4, 7.1) 6.8 (6.4, 7.1) 0.0 (-0.5, 0.5) 0.00 
Weight loss  26.2 (25.6, 26.8) 25.8 (25.2, 26.5) 0.4 (-0.5, 1.3) 0.01 
Healthcare utilization, 2006 to exposure start 
Inpatient admissions, median 
(25th, 75th percentile)  b 3 (1, 6) 3 (2, 5) 0 (0, 0) - e 
Emergency visits, median  (25th, 
75th percentile)  b 4 (2, 7) 4 (2, 7) 0 (0, 0) - e 
Clinic visits, median  (25th, 75th 
percentile)  b 42 (21, 70) 45 (24, 73) -3 (-4, -2) - e 
Home health days , median  
(25th, 75th percentile) b 6 (0, 31) 7 (0, 30) -1 (-1.6, -0.4) 0.04 
Use of SNF, % (95% CI) a 52.6 (51.9, 53.3) 46.5 (45.7, 47.2) 6.2 (5.1, 7.2) 0.12 
Active cancer treatment, % (95% 
CI) a f 35.5 (34.8, 36.2) 44.5 (43.8, 45.2) -9 (-10, -8) -0.18 
Daily expenses, year prior to 
exposure start, $ (95% CI) a $148 (146, 150) $145 (143, 147) $3 (0, 5) 0.02 
        
Table 1 shows variables used for coarsened exact matching and other measures of health and care 
utilization in the baseline period before exposure start, i.e., before the start of hospice or the equivalent 
period for non-hospice beneficiaries. The third column shows mean or median differences between 
groups, calculated as described below, and the last column shows standardized differences between 
groups.  
a For normally-distributed and binary variables, we report means and proportions, respectively, with 95% 
confidence intervals in parentheses. Differences are calculated by t-test and proportion test, 
respectively. 
b For non-normally-distributed variables, we report medians, with inter-quartile range in parentheses. 
Differences are calculated by quantile regression. 
c Gagne comorbidity score, measured on a composite scale synthesizing Elixhauser and Charlson 
indices; scale ranges from -2 to 26. 
d Standardized difference is the difference in group means divided by the common standard deviation. 
e Standardized difference cannot be calculated for count variables. 
f Active cancer treatment refers to chemotherapy or surgery 
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Table 2. Care utilization during exposure periods in the last year of life 
Matched cohort 
Non-hospice Hospice  Risk ratio 
  (N=18,165) (N=18,165)  
Hospital admission, % (95% CI) 65.1 (64.4, 65.8) 42.3 (41.5, 43.0) 1.5 (1.5, 1.6) 
P
rim
ar
y 
IC
D
 c
od
e 
(d
is
ch
ar
ge
) 
Sepsis  10 (9.5, 10.4) 3.4 (3.1, 3.7) 2.9 (2.7, 3.2) 
Pneumonia 4.4 (4.1, 4.7) 2.1 (1.9, 2.3) 2.1 (1.8, 2.3) 
Acute/chronic respiratory failure a 3.9 (3.6, 4.2) 1.1 (1, 1.3) 3.5 (3, 4.1) 
Pneumonitis (aspiration) 2.3 (2.1, 2.5) 1.0 (0.8, 1.1) 2.3 (1.9, 2.7) 
Acute kidney failure 2.2 (2, 2.5) 1.6 (1.4, 1.8) 1.4 (1.2, 1.6) 
Neoplasm of bronchus and lung 2.1 (1.9, 2.3) 1.5 (1.4, 1.7) 1.3 (1.1, 1.6) 
COPD exacerbation 1.4 (1.2, 1.6) 0.6 (0.5, 0.7) 2.5 (2, 3.1) 
Subendocardial infarction 1.3 (1.2, 1.5) 0.4 (0.3, 0.5) 3.6 (2.8, 4.7) 
Urinary tract infection  1.2 (1.1, 1.4) 0.6 (0.5, 0.8) 1.9 (1.5, 2.3) 
Cerebral artery occlusion (stroke)  1.0 (0.9, 1.2) 0.8 (0.6, 0.9) 1.4 (1.2, 1.8) 
ICU admission, % (95% CI) 35.8 (35.1, 36.5) 14.8 (14.3, 15.3) 2.4 (2.3, 2.5) 
ICU  27 (26.4, 27.7) 8.4 (8, 8.8) 3.2 (3, 3.4) 
Step-down or intermediate  10.1 (9.6, 10.5) 6.5 (6.1, 6.8) 1.6 (1.5, 1.7) 
Invasive procedures, % (95% CI) 51.0 (50.3, 51.7) 26.7 (26.1, 27.4) 1.9 (1.9, 2.0) 
Insertion of venous catheter 21.4 (20.8, 22.0) 7 (6.6, 7.4) 3.1 (2.9, 3.3) 
Endotracheal intubation  19.3 (18.8, 19.9) 2.7 (2.4, 2.9) 7.3 (6.6, 8.0) 
Packed cell transfusion 15.6 (15.1, 16.2) 8.7 (8.3, 9.1) 1.8 (1.7, 1.9) 
Platelet or plasma transfusion  6.3 (5.9, 6.6) 2.9 (2.6, 3.1) 2.2 (2, 2.4) 
Non-invasive ventilation  5.9 (5.6, 6.3) 1.7 (1.5, 1.9) 3.4 (3, 3.9) 
Thoracentesis 4.3 (4, 4.6) 2.5 (2.3, 2.8) 1.7 (1.5, 1.9) 
Hemodialysis 4.1 (3.8, 4.4) 1.2 (1, 1.3) 3.6 (3.1, 4.2) 
Cardiopulmonary resuscitation 4.0 (3.7, 4.2) 0.2 (0.1, 0.2) 21.8 (15.4, 30.8) 
Closed bronchial biopsy 3.8 (3.5, 4.1) 1.2 (1, 1.3) 3.3 (2.8, 3.9) 
Arterial catheterization 3.5 (3.2, 3.8) 0.4 (0.3, 0.5) 8.8 (6.9, 11.1) 
Death in hospital or SNF, % (95% CI)  74.1 (73.5, 74.8) 14 (13.5, 14.5) 5.3 (5.1, 5.5) 
Acute care hospital b 50.2 (49.5, 51) 3.4 (3.2, 3.7) 14.6 (13.5, 15.8) 
Long-term hospital or SNF c 23.9 (23.3, 24.5) 10.5 (10.1, 11.0) 2.3 (2.2, 2.4) 
Table 2 shows health care utilization during exposure periods (i.e., hospice care, or the equivalent 
period before death for non-hospice beneficiaries) in the last year of life: percent of beneficiaries 
with hospital admission, ICU stay, procedure, and place of death, with 95% confidence intervals. 
The last column shows the ratio of hospice to non-hospice percentage, calculated as proportion of 
non-hospice over hospice beneficiaries, with 95% confidence interval (calculated as a relative risk). 
a Combines ICD codes 518.81 and 518.84 
b Percent of beneficiaries with an inpatient facility claim on day of death.  
c  Percent of beneficiaries with a claim from a long-term care hospital or skilled nursing facility on 
day of death. Data on SNFs are incomplete because of Medicare restrictions on the number of SNF 
days reimbursed per year, so these should be seen as minimum estimates for both groups.  
COPD denotes chronic obstructive pulmonary disease 
ICD denotes International Classification of Disease codes 
ICU denotes intensive care unit  
SNF denotes skilled nursing facility  
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Table 3. Total costs in the last year of life 
Exposure 
period 
length 
(weeks) 
Weeks from 
diagnosis 
to death 
(95% CI) 
Matched 
pairs (n) 
Total costs, last year of life, mean (95 % CI)  
Non-hospice Hospice Difference 
1 58 6922 $71,582 $66,779 $4,803 
(57, 60)  ($70,027, 73,137)  ($65,470, 68,087)  ($2,933, 6,674) 
2 57 3138 $70,987 $63,139 $7,848 
(55, 58)  ($68,680, 73,294)  ($61,322, 64,955)  ($5,141, 10,555) 
3-4 62 2783 $72,660 $59,595 $13,065 
(60, 64)  ($70,177, 75,144)  ($57,719, 61,471)  ($10,201, 15,930) 
5-8 67 2231 $74,890 $56,986 $17,903 
(65, 69)  ($71,910, 77,869)  ($55,098, 58,875)  ($14,543, 21,264) 
9-26 91 2161 $72,432 $60,326 $12,106 
(88, 93)  ($69,504, 75,360)  ($58,518, 62,134)  ($8,821, 15,392) 
27-52  118 556 $66,035 $65,300 $735 
(114, 122)  ($60,718, 71,352)  ($62,687, 67,913)  (-$5,131, 6,601) 
> 52  152 374 $48,981 $56,368 -$7,387 
  (148, 157)    ($44,206, 53,755)  ($52,931, 59,805)  (-$13,289, -1,485) 
Total 67 18,165 $71,517 $62,819 $8,697 
(67, 68) ($70,543, 72,490) ($62,082, 63,557)  ($7,560, 9,835) 
Table 3 shows cumulative total costs for non-hospice and hospice beneficiaries, separated by the 
length of the exposure period (i.e., period of non-hospice or hospice care before death).  
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